EZH2 and diffuse large B-cell lymphoma: Five DLBCL cell lines (EZH2 WT: SU-DHL-16, HBL-1 and U2932; EZH2 MT: KARPAS-422 and SU-DHL-6) were treated with indicated concentrations of SHR2554 and HBI8000 for 72 h.